Stevenage Bioscience Catalyst Board appoints Andrew Waters as Chief Executive Officer

The Board of Stevenage Bioscience Catalyst is delighted to announce the promotion of Andrew Waters from his current position of Chief Financial Officer & Interim CEO to the position of Chief Executive Officer.

Andrew has a First Class Physics degree from Imperial College London, is an FCA Chartered Accountant and has worked almost his whole career within the Life Sciences industry. After 4 years at PwC London, Andrew spent 16 years at GSK in a number of positions across R&D and the commercial business including time working overseas in US, Denmark and Netherlands. He then spent 6 years co-founding and developing a start-up business which raised over £40 million from private equity and successfully developed and launched OTC medicines into the US market achieving national scale. Andrew subsequently held public company CFO appointments before joining SBC in September 2023 as CFO. He was appointed into the role of CFO & Interim CEO in January 2025.

Professor Jackie Hunter PhD DSc CBE, Chair of Stevenage Bioscience Catalyst, said:

Andrew brings a depth of knowledge and commercial experience to the SBC that will be of great value to the business and the companies it serves.

Andrew Waters said:

It is a very great privilege to be invited to serve as Chief Executive Officer. I’m excited by this opportunity to drive solutions for the UK life sciences sector despite prevailing industry uncertainties.